- Pharmaron’s net income for Q1 totaled 230.6 million yuan, a decrease from last year’s report during the same period.
- This constitutes a 34% decrease in net income compared to the previous year.
- The company’s revenue also decreased, reporting 2.67 billion yuan, a 2% drop on year-on-year basis.
- From a market perspective, there are more investors buying Pharmaron stocks compared to those selling or holding. Specifically, there are a total of 23 buys, 2 holds, and 3 sells for the company’s stocks.
- It is important to note, all comparisons to the past results are strictly based on information reported by the company in their original disclosures.
A look at Pharmaron Beijing Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Pharmaron Beijing Co., Ltd. is positioned favorably for long-term growth based on a recent analysis of its Smart Scores. With a growth score of 4 out of 5, the company shows strong potential for expansion and development in the coming years. Additionally, Pharmaron Beijing received solid scores in value, dividend, and resilience, indicating a stable and promising outlook for investors. However, its momentum score of 2 suggests a slower pace of upward movement in the market.
Pharmaron Beijing’s diversified offerings in drug discovery, development, manufacturing, and testing services for medical devices and clinic research provide a solid foundation for sustained growth. Operating primarily in China, the company’s strategic positioning in the rapidly growing healthcare sector bodes well for its long-term success, supported by its positive Smart Scores across key factors.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
